Commercial and Social Value of Pharmaceutical Industry-led Access Programs: Conceptual Framework and Descriptive Analysis

IF 1.9 3区 医学 Q3 HEALTH POLICY & SERVICES Health Systems & Reform Pub Date : 2022-01-01 DOI:10.1080/23288604.2022.2057831
Joshua Smith-Sreen, A. C. Heerdegen, V. Wirtz, Priyanka Kulkarni, Melissa Machado, P. Rockers
{"title":"Commercial and Social Value of Pharmaceutical Industry-led Access Programs: Conceptual Framework and Descriptive Analysis","authors":"Joshua Smith-Sreen, A. C. Heerdegen, V. Wirtz, Priyanka Kulkarni, Melissa Machado, P. Rockers","doi":"10.1080/23288604.2022.2057831","DOIUrl":null,"url":null,"abstract":"ABSTRACT Pharmaceutical industry-led access programs are growing in number globally and are increasingly adopting a hybrid approach intended to generate commercial and social value in parallel. We developed and applied a new conceptual framework in a descriptive analysis of observable indicators measuring commercial and social value for 91 programs registered in the Access Observatory. We found that most programs had features consistent with the generation of commercial value, directly through revenue generation (50.0%), or indirectly by creating competitive advantage (70.3%). We also found that most programs were implemented in countries where the company has commercial products registered (85.5%). While many programs had features consistent with the generation of social value, it was difficult to ascertain the level of that value because most did not share data (83.5%) and had not been evaluated (74.7%). Future efforts by the global health community and the pharmaceutical industry should focus on strengthening measurement and reporting on commercial and social indicators of industry-led access programs.","PeriodicalId":46168,"journal":{"name":"Health Systems & Reform","volume":"81 1","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Health Systems & Reform","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/23288604.2022.2057831","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEALTH POLICY & SERVICES","Score":null,"Total":0}
引用次数: 1

Abstract

ABSTRACT Pharmaceutical industry-led access programs are growing in number globally and are increasingly adopting a hybrid approach intended to generate commercial and social value in parallel. We developed and applied a new conceptual framework in a descriptive analysis of observable indicators measuring commercial and social value for 91 programs registered in the Access Observatory. We found that most programs had features consistent with the generation of commercial value, directly through revenue generation (50.0%), or indirectly by creating competitive advantage (70.3%). We also found that most programs were implemented in countries where the company has commercial products registered (85.5%). While many programs had features consistent with the generation of social value, it was difficult to ascertain the level of that value because most did not share data (83.5%) and had not been evaluated (74.7%). Future efforts by the global health community and the pharmaceutical industry should focus on strengthening measurement and reporting on commercial and social indicators of industry-led access programs.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
制药行业主导的准入计划的商业和社会价值:概念框架和描述性分析
制药行业主导的可及性项目在全球范围内数量不断增长,并且越来越多地采用旨在同时产生商业和社会价值的混合方法。我们开发并应用了一个新的概念框架,对在访问观察站注册的91个项目的商业和社会价值衡量指标进行了描述性分析。我们发现,大多数项目具有与商业价值的产生相一致的特征,直接通过创收(50.0%),或间接通过创造竞争优势(70.3%)。我们还发现,大多数项目是在公司有商业产品注册的国家实施的(85.5%)。虽然许多项目具有与社会价值产生相一致的特征,但由于大多数项目没有共享数据(83.5%)和没有进行评估(74.7%),因此很难确定该价值的水平。全球卫生界和制药行业今后的努力应侧重于加强对行业主导的可及性项目的商业和社会指标的测量和报告。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
5.50
自引率
9.80%
发文量
35
审稿时长
16 weeks
期刊最新文献
Strengths and Weaknesses of Strategic Health Purchasing for Universal Health Coverage in Rwanda Strategic Health Purchasing Progress Mapping: A Spotlight on Ghana’s National Health Insurance Scheme Strategic Health Purchasing in Nigeria: Investigating Governance and Institutional Capacities within Federal Tax-Funded Health Schemes and the Formal Sector Social Health Insurance Programme Integrating Venezuelan Migrants into the Colombian Health System during COVID-19 Decentralization Can Improve Equity, but Can It Be Sustained?
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1